Release date: 2006-10-17
Merck Unveils a Groundbreaking Rapid Detection Method for Legionella
In October 2006, Merck KGaA introduced a revolutionary lateral flow test designed to detect all species of Legionella bacteria in a single, fast process. This new method, known as Duopath Legionella, allows for the simultaneous identification of various Legionella strains, including the most prevalent one, Legionella pneumophila, using the same testing procedure.
The test is particularly useful for confirming suspected colonies that have been grown on specialized media such as Buffered Charcoal Yeast Extract (BCYE) agar or BCYE supplemented with selective components for Legionella. This makes it ideal for use in water and environmental samples, where early detection is critical to preventing outbreaks.
One of the key advantages of the Duopath Legionella assay is its high sensitivity, which significantly reduces the chances of false-negative results. In a comparative study against the traditional latex agglutination method, the Duopath Legionella test demonstrated 100% sensitivity for Legionella pneumophila and 92% for other Legionella species. In contrast, the latex method only achieved 98% and 37% sensitivity, respectively. These results highlight the superior performance of the new test, making it a more reliable option for laboratories and public health professionals.
This innovation marks a major step forward in Legionella detection, offering faster, more accurate, and more efficient testing options. As awareness of waterborne pathogens continues to grow, tools like Duopath Legionella play a crucial role in safeguarding public health.
—— Information from: Meditech Medical Network
Active Pharmaceutical Ingredient
FOSHAN PHARMA CO., LTD. , https://www.forepharm.com